ArticleBioMed research international2026
Elevated Fatty Acid Binding Protein 4 (FABP4) Associated With Liver Damage and Kidney Complications in Thalassemia Patients.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elevated Fatty Acid Binding Protein 4 (FABP4) Associated With Liver Damage and Kidney Complications in Thalassemia Patients.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThalassemia is considered a significant health concern. Previous studies had shown that numerous adipokines, including fatty acid binding protein 4 (FABP4), might contribute to the development of complications in thalassemia.
objectivesThis study is aimed at investigating FABP4 levels in thalassemia major patients receiving regular blood transfusions as well as to explore the association between FABP4 and target organ functioning as kidney and liver.
methodSerum samples were collected from 154 individuals with thalassemia major and subjected to various analyses, including hematological assessments, biochemical evaluations (kidney and liver functions), and immunological screenings using enzyme-linked immunosorbent assay (ELISA).
resultsExamination of sociodemographic and disease-related factors indicated osteoporosis emerging as the predominant comorbidity. Elevated ferritin levels, an increased platelets (PLT) count, higher nucleated red blood cell (NRBC) count, and elevated bilirubin (BIL) levels in patient serum were observed. Conversely, creatinine levels were significantly low, with a mean of 21.7 and 25.4 μmol/L in females and males, respectively. FABP4 levels exhibited more frequent increases in females of p value = 0.03, particularly in the age groups of (13-18, 19-30) years; respectively, FABP4 levels had a significant difference of p value = 0.003 with the aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio.
conclusionA significant difference was seen between serum FABP4 and bilirubin and AST/ALT ratio, showing a connection between serum FABP4 and liver injury and kidney complications. Consequently, while further studies are essential for a comprehensive exploration of this hypothesis, serum FABP4 may have a potential role in chronic diseases in thalassemia patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.